Guidant To Push Drug Eluting Stent Program In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Cordis/Guidant drug-eluting stent technology integration slows as Cordis addresses FDA warning letter citing regulatory, quality issues. Champion DES fracture issue solved, Guidant says; redesigned Champion premarket filings to occur in first quarter next year.